Key result
Intrapericardial bleomycin offers an effective, well-tolerated alternative to surgical drainage for malignant pericardial effusion.
Why the study?
Malignant pericardial effusion is difficult to treat due to high recurrence rates and limitations of surgery in frail patients, with limited evidence on sclerosing agents like bleomycin.
Does intrapericardial bleomycin improve management and tolerability in patients with malignant pericardial effusion compared to surgical options or other sclerosing agents?
Does intrapericardial bleomycin improve management and tolerability in patients with malignant pericardial effusion compared to surgical options or other sclerosing agents?
Intrapericardial bleomycin is highlighted as an effective, well-tolerated, and less invasive palliative alternative to surgical drainage for managing malignant pericardial effusion.
Answers are grounded in this paper and cite their sources.
Optimal management of malignant pericardial effusion remains uncertain; limited Level 5 evidence leaves open the preferred strategy.
Plain Language Summary Malignant pericardial effusion, a complication of advanced malignancy, carries a poor prognosis and may be life-threatening in cases of cardiac tamponade. Treatment is challenging due to high recurrence rates. Management options include surgical pericardial window, extended catheter drainage, or intrapericardial sclerosing agents. While surgery remains the most definitive option for eligible patients, frailty and procedural morbidity are major limitations. Limited evidence suggests sclerosing agents provide comparable efficacy with improved tolerability. Bleomycin, a glycopeptide antibiotic with dual cytotoxic and sclerosing action, has emerged as a promising alternative, with recent evidence demonstrating efficacy similar to surgical drainage and superior tolerability compared to other agents. We highlight the advantages of bleomycin and its potential for broader adoption as an effective, well-tolerated, and palliative option in managing malignant pericardial effusion. Plain Language SummaryMalignant pericardial effusion, often seen in advanced cancer, can lead to life-threatening cardiac tamponade and is difficult to treat due to frequent recurrence. Traditional management includes surgery, catheter drainage, or sclerosing agents, but surgery is limited by patient frailty and risks. Bleomycin, a drug with both cytotoxic and sclerosing properties, shows promise as an effective and better-tolerated alternative to surgery. Recent studies suggest bleomycin offers similar efficacy to surgical drainage with fewer side effects, making it a potentially valuable option for palliative care in patients with malignant pericardial effusion. Text is machine generated and may contain inaccuracies. View Plain Language Summary safety and compliance information
No takes yet. Share an insight, caveat, or question.
Rayes et al. (2025) conducted a review in Malignant pericardial effusion. Intrapericardial bleomycin vs. Surgical drainage or other sclerosing agents was evaluated. Intrapericardial bleomycin is a promising, effective, and well-tolerated palliative alternative to surgical drainage for managing malignant pericardial effusion.
Synapse has enriched 10 related papers. Consider them for comparative context: